Study of a New Technique for Imaging Pancreatic Cancer

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: BioNTech SE

Criteria

Inclusion Criteria:

PART I : ESCALATION, EXPANSION, RE-ENTRY COHORTS:

• Histologically confirmed, locally-advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive malignancies

PART II: PRE-SURGERY COHORT ONLY:

• Biopsy-proven or high suspicion on imaging for pancreatic ductal adenocarcinoma (PDAC) (Stage T2 and T3) and

• Patient scheduled to undergo surgery as standard of care for their pancreatic adenocarcinoma OR

• Patients with Intraductal papillary mucinous neoplasm (IPMN) scheduled to undergo surgery as standard of care.

The suspicion for pancreatic carcinoma and decision for surgery will be based on review of imaging and clinical findings in the disease management team discussion including surgeon and radiologist.

PART I and II:

• Signed, informed consent

• Age 18 or more years

• At least one lesion by CT or MRI ≥ 2 cm, unless determine otherwise for pre-surgery cohort subjects

• CA19-9 serum level:

• For Part I: >ULN or CA19-9 positive biopsy (optional);

• For Part II ( presurgical cohort): CA19-9 serum level (normal or high levels are allowed) or CA19-9 positive biopsy (optional)

• ECOG performance status of 0 to 2

• Adequate laboratory parameters including:

• Absolute neutrophil count (ANC) ≥1.5 x 10^9/L

• Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)

• Platelet count >75,000/ mm^3

• AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN

• Total bilirubin ≤1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, ≤3x the upper limit of normal

• Creatinine (serum or plasma) ≤ 1.5 x ULN or eGFR>50 mL/min

PART I: ESCALATION, EXPANSION, RE-ENTRY COHORTS:

• Willingness to participate in collection of pharmacokinetic samples

Exclusion Criteria:

• Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy

• Major surgery other than diagnostic surgery within 4 weeks of Study Day 1

• History of anaphylactic reaction to human, or humanized, antibody

• Other on-going cancer therapy or investigational agents (except MVT-5873)

• Known history of HIV

• Pregnant or currently breast-feeding

• Psychiatric illness/social situations that would interfere with compliance with study requirements

• Prior entry onto this protocol 3 or more times (e.g., subjects may enter this protocol and be imaged up to 3 times)